Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.

المؤلف	Imamovic, Denira
المؤلف	Vranic, Semir
تاريخ الإتاحة	2019-04-04T08:19:05Z
تاريخ النشر	2017-12-01
اسم المنشور	Annals of translational medicine
المعرّف	http://dx.doi.org/10.21037/atm.2017.09.32
الاقتباس	Imamovic D, Vranic S. Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4—a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors. Ann Transl Med 2017;5(23):467. doi: 10.21037/atm.2017.09.32
الرقم المعياري الدولي للكتاب	2305-5839
معرّف المصادر الموحد	http://hdl.handle.net/10576/11469
الملخص	CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors
اللغة	en
الناشر	AME Publishing Company
الموضوع	targeted therapy immune checkpoint inhibitors PD-L1 cancer
العنوان	Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.
النوع	Article
رقم العدد	23
رقم المجلد	5
dc.accessType	Open Access